To include your compound in the COVID-19 Resource Center, submit it here.

J&J appeals district court decision invalidating Zytiga patent

Johnson & Johnson (NYSE:JNJ) on Oct. 31 filed to appeal a district court decision that will permit generic versions of prostate cancer drug Zytiga abiraterone acetate to launch after

Read the full 297 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE